Nurix Therapeutics partners with Roche on BTK degrader drug deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
June 8, 2026 1:00 AM EDTStrategic collaboration combines Nurixs leadership in targeted protein degradation with Roches portfolio of B-cell targeted therapies and global clinical and commercialization footprint
Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies
Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU)
Nurix to receive an upfront cash payment of $700... More
